Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...

Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

This segment is sponsored by Boehringer Ingelheim and Eli Lilly and Company. What do hip-hop and kidney disease have in ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...

Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches BARCELONA, Spain, Nov. 14, 2024 /PRNewswire/ -- Veeva Systems ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...